Abstract:XIST RNA is heavily studied for its role in fundamental epigenetics and X-chromosome inactivation; however, the translational potential of this singular RNA has been much less explored. This article combines elements of a review on XIST biology with our perspective on the translational prospects and challenges of XIST transgenics. We first briefly review aspects of XIST RNA basic biology that are key to its translational relevance, and then discuss recent efforts to develop translational utility of XIST for chromosome dosage disorders, particularly Down syndrome (DS). Remarkably, it was shown in vitro that expression of an XIST transgene inserted into one chromosome 21 can comprehensively silence that chromosome and "dosage compensate" Trisomy 21, the cause of DS. Here we summarize recent findings and discuss potential paths whereby ability to induce "trisomy silencing" can advance translational research for new therapeutic strategies. Despite its common nature, the underlying biology for various aspects of DS, including cell types and pathways impacted (and when), is poorly understood. Recent studies show that an inducible iPSC system to dosage-correct chromosome 21 can provide a powerful approach to unravel the cells and pathways directly impacted, and the developmental timing, information key to design pharmacotherapeutics. In addition, we discuss prospects of a more far-reaching and challenging possibility that XIST itself could be developed into a therapeutic agent, for targeted cellular "chromosome therapy". A few rare case studies of imbalanced X;autosome translocations indicate that natural XIST can rescue an otherwise lethal trisomy. The potential efficacy of XIST transgenes later in development faces substantial biological and technical challenges, although recent findings are encouraging, and technology is rapidly evolving. Hence, it is compelling to consider the transformative possibility that XIST-mediated chromosome therapy may ultimately be developed, for specific pathologies seen in DS, or other duplication disorders.

Down syndrome and the complexity of genome dosage imbalance

Genetic analysis of Down syndrome facilitated by mouse chromosome engineering.

Human Chromosome 21 Orthologous Region on Mouse Chromosome 17 is a Major Determinant of Down Syndrome-Related Developmental Cognitive Deficits.

Transcriptional consequences of trisomy 21 on neural induction

A dynamic in vitro model of Down syndrome neurogenesis with trisomy 21 gene dosage correction

Deficits in Human Trisomy 21 Ipscs and Neurons

The burden of trisomy 21 disrupts the proteostasis network in Down syndrome

Consequences of trisomy 21 for brain development in Down syndrome

Trisomy 21-driven metabolite alterations are linked to cellular injuries in Down syndrome

A new mouse model for Down syndrome

Beyond Trisomy 21: Phenotypic Variability in People with Down Syndrome Explained by Further Chromosome Mis-segregation and Mosaic Aneuploidy

Single-nucleus RNA sequencing reveals cell type-specific transcriptome alterations of Down syndrome hippocampus using the Dp16 mouse model

Chromosomal and cellular therapeutic approaches for Down syndrome: A research update

Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte Differentiation and Myelination

Functional analysis of genes implicated in Down syndrome: 1. Cognitive abilities in mice transpolygenic for Down Syndrome Chromosomal Region-1 (DCR-1)

Genome-wide expression analysis in Down syndrome: insight into immunodeficiency

Trisomy silencing by XIST: translational prospects and challenges

Genetic dissection of triplicated chromosome 21 orthologs yields varying skeletal traits in Down syndrome model mice

Consequences of aneuploidy in human fibroblasts with trisomy 21

Interaction of sexual dimorphism and gene dosage imbalance in skeletal deficits associated with Down syndrome

Modulation of Global Gene Expression by Aneuploidy and CNV of Dosage Sensitive Regulatory Genes